Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FF/VI once daily versus fluticasone propionate/salmeterol twice daily in COPD
2012-003106-27Phase 3Completed
- Sponsor
- GSK
- Start
- Aug 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of fluticasone, vilanterol, fluticasone propionate and salmeterol in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by GSK. Primary endpoint: Change from baseline trough in 24-hour weighted-mean serial FEV1 at the end of 12 weeks of treatment on Treatment Day 84. Started Aug 2012; status: completed.
02
Drugs
fluticasonevilanterolfluticasone propionatesalmeterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-003106-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003106-27.